Degradation of the extracellular matrix and basement membrane is a critical step in tumor progression. Matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP 2) act in a coordinated manner to form an integrated system involved in ovarian cancer (OC) progression. In this study, the authors describe the expression of TIMP-2 detected by immunohistochemistry in 6 OC cell lines and in 43 malignant epithelial ovarian tumors (in tumor and stromal compartments) in sections originating from primary laparotomies. No significant correlations between overall and progression-free survival and TIMP-2 expression in tumor compartment were observed. The analysis demonstrated a significant association between enhanced stromal expression of TIMP-2 and better clinical response to cisplatin-and paclitaxelbased chemotherapy. Increased expression of TIMP-2 in the stromal compartment and simultaneous overexpression in both stromal and tumor compartments strongly correlated with increased survival. No significant correlations were found in vitro between resistance to cisplatin, paclitaxel, or topotecan and the expression of TIMP-2 in the OC cell lines, suggesting stromal influences on tumor chemoresistance in the physiological environment. This study supports the concept of TIMP-2 expression in the stromal compartment of OC as a promising marker of prognosis and response to cisplatin-and paclitaxelbased chemotherapy in OC patients. (J Histochem Cytochem 60:491-501, 2012) 
Ovarian cancer (OC) is one of the most common gyneco logic malignancies, representing a cancer type with a high mortality rate due to its advanced stage at diagnosis (Inter national Federation of Gynecology and Obstetrics [FIGO] III and IV) (Manenti et al. 2003) . The clinical symptoms of OC, especially in the early stages, are nonspecific; therefore, approximately 75% of women have an advanced stage of the disease at diagnosis, which is consequently associated with poor outcome. Firstline therapy in advanced ovarian can cer commonly consists of surgical resections followed by cisplatin and taxanebased chemotherapy. Despite a high initial response rate, most patients will relapse, which is strongly related to acquired drug resistance . Knowl edge of biological mechanisms mediating chemoresistance may lead to new and more effective therapeutic strategies.
Breakage or degradation of the extracellular matrix (ECM) and basement membrane (BM) is a critical step in tumor progression. Several classes of proteases are involved in tumor invasion by degradation of type IV collagen, which is the main component of the BM. The most important group of proteins is a family of more than 20 extracellular zincdependent proteolytic enzymes, that is, the matrix metalloproteinases (MMPs) (Gershtein et al. 2010) . The tis sue inhibitors of metalloproteinases (TIMPs) are the main physiologic inhibitors of MMPs. TIMPs are secreted pro teins that can form complexes with individual MMPs and regulate the activity of specific MMPs. Maintaining the bal ance between the levels of MMPs and TIMPs is crucial for ECM stability.
TIMP2 is one of four wellknown members of the TIMP family: TIMP1, TIMP2, TIMP3, and TIMP4. All of these, except for TIMP3, are secreted in soluble form, whereas TIMP3 is bound to ECM proteins as an insoluble type (Sternlicht and Werb, 2001) . The pleiotropic and mul tifaceted role of TIMPs in carcinogenesis has been widely discussed in previous studies (Baker et al. 2002; Jiang et al. 2002) . The physiological function of TIMP2 is in the inhi bition of MMP2 activation, but there are data to show that an increasing level of TIMP2 can promote MMP2 activity and invasion in some tumors (Lu et al. 2004 ). Indeed, for over a decade, TIMPs have been described as tumorpro moting factors that are engaged in cellular proliferation (Hayakawa et al. 1992) or as inhibitors of angiogenesis in MMPindependent pathways (Fernandez et al. 2003) . Taking into account these paradoxical results, further stud ies are needed to fully determine the role of TIMPs in human cancer development.
MMP2/TIMP2 act in a coordinated manner to form an integrated system involved in OC progression. Data on the function of TIMP2 in carcinogenesis of the ovary are inconsistent and seem to depend on the detection methods used and the histological type of tumors included in the studies (Davidson et al. 2002; Okamoto et al. 2003; Rauvala et al. 2005; Kim et al. 2006 ). Davidson et al. (2002) revealed, by using mRNA in situ hybridization, that TIMP2 expres sion is a valid marker of poor outcome in advancedstaged OC. However, Okamoto et al. (2003) showed a decreased level of TIMP2 in ovarian carcinomas, as compared with normal ovarian cells.
This study aimed to assess the prognostic and predictive value of immunohistochemical examination of TIMP2 expression in patients with ovarian cancer. We examined the relationships between the expression of TIMP2 in tumor and stromal cells (tumor and stromal compartments) and the clinical data of the studied patients. In addition, TIMP2 immunoexpression was investigated in six ovarian cancer cell lines (EFO 21, ES2, Mdah 2774, OAW 42, OVCAR3, and SKOV3) . Because chemoresistance is a major obstacle in the treatment of ovarian cancer, an analy sis of cisplatin, paclitaxel, and topotecan sensitivity in the analyzed cell lines was also carried out.
Materials and Methods

Cell Culture
Human carcinoma cells were grown in Leibovitz L15 medium (Biowhittaker; Walkersville, MD) supplemented with 10% fetal calf serum (FCS; Gibco/BRL, Grand Island, NY), 1 mM Lglutamine, 6.25 mg/1 fetuin, 80 IE/1 insulin, 2.5 mg/ml transferrin, 0.5 g/1 glucose, 1.1 g/1 NaHCO 3 , 1% minimal essential vitamins, and 20,000 kIE/1 trasylol in a humidified atmosphere of 5% CO 2 at 37C, as described previously (Materna et al. 2005 Kowalski et al. 2005; Surowiak, Materna, Kaplenko, Spaczynski, Dolinska Krajewska, et al. 2006 
Resistance Tests
The drugs were used in their commercially available form. Each drug was applied to the cells in three concentrations (C1, C2, C3). C1 = 10 -1 × C2 and C3 = 10 × C2. Concentration C2 was deduced from levels assessed to be clinically achievable in tumor tissue, as discussed previ ously (Györffy et al. 2006) (Table 1) .
In each experiment, 500 cells/microtiter dish were seeded onto 96well plates. After 2 days, the pre-control cells were fixed and stained using sulforhodamine B (SRB) (Györffy et al. 2006) . At the same time, triplicate cultures were pre pared with all three of the studied drugs at C1, C2, and C3 concentrations. After 4 days, incubation was terminated by replacing the medium with 10% trichloroacetic acid, fol lowed by incubation at 4C for 1 hr. Subsequently, the plates were washed five times with water and stained by adding 100 µl 0.4% SRB (Sigma; St. Louis, MO) in 1% acetic acid for 10 min at room temperature. Washing the plates five times with 1% acetic acid eliminated unbound dye. After air drying and resolubilization of the proteinbound dye in 10 mM TrisHCl (pH 8.0), absorbance was read at 562 nm in an ElisaReader (EL 340 Microplate Bio Kinetics Reader; BIO TEK Instruments, Winooski, VT). The measurements were performed in triplicate in three independent experiments. For calculation of the resistance index (RI) values, the aver ages of all nine measurements were used.
The RI was estimated by the following formula: RI = (n post /n pre ) × [(n2 -n pre )/(n post -n pre ) × 100],
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where n pre is the medium absorbance value of the precontrol at C2 concentration, n post is the medium absorbance value of control, and n2 is the medium absorbance value of stained cells tested with a chosen concentration of the stud ied drug. At the C2 concentration of topotecan, we did not have enough resistant and sensitive cell lines to be able to perform a robust statistical calculation; therefore, we used C3. Only the cell lines that fulfilled the following quality criteria of n post > n pre and deviation in cell growth within repetitions <15% were included in the evaluation. Cells exhibiting the lowest third RI results were designated as sensitive, the top third as resistant, and the remaining cells as intermediate.
Patients
Fortythree patients who underwent surgery from 1999-2002 due to ovarian carcinoma at the Department of Gynaecology and Obstetrics, University Medical School in Poznan (Poland) were included in the study. The cases were selected based on availability of tissue and were not strati fied for known preoperative or pathological prognostic factors. The study was approved by an institutional review board (IRB), and the patients gave their informed consent before being included in the study. Following primary lapa rotomy (PL), all of the patients were subjected to chemo therapy using cisplatinbased schemes (Table 2) . Thirtysix patients from the same group were also subjected to sec ondary cytoreductions (SCR). In seven cases, no second look procedure was performed due to advancement of the disease. In six cases, no tumor cells were detected in the material originating from the secondlook procedure. The patients were monitored by periodic medical checkups, CA125 serum levels, and ultrasonographic and radiologi cal examinations. During the followup period, 22 patients (51%) had recurrent disease and 13 patients (30%) died of the disease. The mean progressionfree survival time was 16.9 months (range, 0-52 months), whereas the mean overallfree survival time was 24.6 months (range, 6-52 months). Only 1 stage I and 1 stage II patients achieved optimal cytoreduction. Tissue samples were fixed in 10% buffered formalin and embedded in paraffin. In each case, hematoxylin and eosinstained preparations were subjected to histopatho logical evaluation by two pathologists. The stage of the tumors was assessed according to the International Federation of Gynaecology and Obstetrics (Sobin et al. 1997 ). The tumors were graded according to the Silverberg grading system (Shimizu et al. 1998 ).
Immunohistochemistry
An immunohistochemical examination was performed retro spectively on tissue samples taken from primary laparoto mies. Formalinfixed, paraffinembedded tissue was freshly cut (4 µm). The sections were mounted on Superfrost slides (Menzel Gläser; Göttingen, Germany), dewaxed with xylene, and gradually hydrated. The activity of endogenous peroxi dase was blocked by 5min exposure to 3% H 2 O 2 . All of the studied sections were boiled for 15 min at 250W in the . DAB (DakoCytomation) was used as a chromogen (7 min, room temperature). All of the sections were counterstained with Meyer's hematoxylin. In this study, Ki67 ) and p53 (Materna et al. 2007 ) expression data, which had been investigated previously in the same group of patients, were reused.
Immunocytochemistry
Immunostaining of TIMP2 was performed using all of the studied cell lines. Cells were grown on microscope slides and fixed in an icecold methanolacetone mixture (1:1) for 10 min. After rehydration, an immunostaining reaction was performed in triplicate as described above.
Evaluation of Immunohistochemical Reaction in Postoperative Cancer Specimens and Immunocytochemical Reaction in Cancer Cell Lines
In this study, we separately evaluated the expression (immunoreactive score [IRS]) in tumor cells (tumor com partment, TIMPc) and in stromal fibroblasts (stromal com partment, TIMPs) of OC specimens originating from laparotomies. For the evaluation of the TIMP2 expression in the stromal compartment, we used only a percentage of the positive cells (0-4) ( Table 3) . Intensity of the immuno histochemical reactions in the tumor compartment and immunocytochemical reactions in cell lines was appraised using the semiquantitative IRS scale, in which intensity of the reaction and percentage of positive cells were scored (Table 3 ). The final result represented a product of scores given for individual traits and ranged between 0 and 12 (Remmele and Stegner 1987) . Intensity of immunohisto chemical reactions was evaluated independently by two pathologists. In cases of divergences, the evaluation was repeated using a doubleheaded microscope.
In addition, cases with high intensity of immunohisto chemical reaction both in the tumor cells (IRS 6-12) and in the stromal fibroblasts (2-4), defined as TIMP2cs = 1, and with low intensity or without reaction, defined as TIMP2cs = 0 (TIMP2c, IRS 0-4; TIMP2s, IRS 0-1), were extracted for statistical analysis.
Statistical Analysis
Statistica 98 PL software (StatSoft, Krakow, Poland) was used for a statistical analysis of the results. The tests used included the ANOVA KruskalWallis rank test, Spearman's rank correlation, KaplanMeier statistics, and logrank tests. In the univariate analysis, we did not find any signifi cant relationships (p>0.05) between the studied clinico pathological parameters (age, histology, grade, CA125 at primary laparotomy level) and overall and progressionfree survival time; therefore, we did not perform a multivariate analysis. Because 95% of the studied patients were in stage FIGO III, we did not investigate the relationships between stage and survival data.
We also performed KaplanMeier statistics and logrank tests on a subgroup of 35 FIGO III patients receiving post surgical platinum and paclitaxelcontaining combination therapy.
Results
Cisplatin, Paclitaxel, and Topotecan Resistance of Cell Lines
The resistance of various human ovarian carcinoma cell lines against treatment with cisplatin, paclitaxel, and topote can was determined by an assessment of the RI, as described in Materials and Methods. An ovarian cancer cell line that was completely resistant to cisplatin, paclitaxel, and topote can was ES2. In turn, the EFO 21 and OVCAR3 cell lines were characterized by a relatively good response to the applied dose of anticancer agents. Mdah 2774 was resistant to cisplatin and topotecan, but the analysis revealed com plete sensitivity to paclitaxel. Furthermore, OAW42 was only resistant to topotecan, and SKOV3 was characterized by sensitivity only to paclitaxel. Figure 1 presents all the results of chemoresistance analysis in the studied cell lines. IRS, immunoreactive score according to Remmele and Stegner (1987) ; TIMP-2, tissue inhibitor of metalloproteinase 2. 
TIMP-2 Immunostaining in Cell Lines
Strong cytoplasmic TIMP2 expression (IRS 12) was shown in EFO 21 cells (Fig. 1) . Moderately enhanced cyto plasmic immunoreactivity was also observed in the ES2 and OVCAR3 cell lines (IRS 6 and 3, respectively). The other cell lines were TIMP2 negative (Fig. 1) . No signifi cant correlations were found between cisplatin, paclitaxel, and topotecan resistance and expression of TIMP2 among the cell lines.
TIMP-2 Expression and Clinicopathological Parameters
In postoperative specimens of ovarian cancer, a cytoplas mic reaction with variable intensity in individual cases (Fig. 2) was observed. Furthermore, we noted strong TIMP2 immunoreactivity in the stromal compartment of ovarian tumors (Fig. 3) . The mean ± SD IRS score of TIMP2 expression in the tumor compartment was 4.69 ± 3.35 (minimum, 0; maximum, 12), and the mean ± SD reactivity of TIMP2 in the stromal compartment was 1.02 ± 1.14 (minimum, 0; maximum, 4). We observed seven cases defined as TIMP2cs = 1 with high intensity of an immunohistochemical reaction, both in the tumor cells (IRS 6-12) and in the stromal fibroblasts (2-4). There were 36 specimens defined as TIMP2cs = 0 with simultaneous low TIMP2 expression intensity or without reaction (TIMP2c, IRS 0-4; TIMP2s, IRS 0-1) in both stromal and tumor compartments. At the first stage of statistical analysis of the relationship between TIMP2 expression and the clinicopathological parameters of patients (age, CA125 serum levels at pri mary laparotomy, histological tumor type, grade and clini cal response to chemotherapy), Spearman's rank correlation and the ANOVA KruskalWallis rank test were used. In addition, correlations between TIMP2 reactivity in the tumor and stromal compartments and immunoreactivity of Ki67 and p53 were examined (Table 4 ).
In cases that responded well (complete response) to cis platin and paclitaxelbased chemotherapy, the immunore activity of TIMP2 expression in the stromal compartment was stronger (p=0.0497) than in patients with progressive disease (Table 4) . Interestingly, we observed a tendency (p=0.0506) for simultaneous Ki67 overexpression and the enhanced reactivity of TIMP2 in the tumor compartment (Table 4 ). Except the abovementioned two relationships, the statistical analysis did not reveal any significant correla tions between TIMP2 expression (in both localizations of expression: in stromal and cancer cells) and other analyzed clinical parameters (Table 4) .
Using the KaplanMeier analysis, overall and progres sionfree survival were compared in patients with low (0-4 IRS) and high (6-12 IRS) expression of TIMP2 in cancer tissue (Figs. 4A, 5A ) and in stromal cells (Figs. 4B, 5B ). In addition, we examined the influence on survival for patients with coexisting expression in the tumor and stromal com partments (Figs. 4C, 5C ). Patients with enhanced immuno reactivity of TIMP2 in the stromal compartment had a significantly increased overall survival (p=0.00008; Fig.   Figure 2 . Immunohistochemical expression of tissue inhibitor of metalloproteinase 2 (TIMP-2) in ovarian cancer tissue. (A) IRS 2, ×200; (B) IRS 12, ×200; (C) IRS 8, ×200; hematoxylin. IRS, immunoreactive score.
TIMP-2 Expression in Ovarian Cancer
497
4B) and progressionfree survival time (p=0.001; Fig. 5B ). No significant correlations between overall survival and progressionfree survival and TIMP2 in the tumor com partment were detected. Interestingly, in cases of simultane ous high expression of TIMP2 in tumor and stromal compartments, we observed that this type of reactivity is strongly correlated with a good clinical outcome (p=0.00056 for overall survival time; Fig. 4C ).
TIMP-2 Expression and Results of Chemotherapy
The relationships between overall and progressionfree survival and expression of TIMP2 in the subgroup of FIGO stage III patients treated with platinumbased drugs and paclitaxel were evaluated. Overexpression of TIMP2 in the stromal compartment in this subgroup was associated (p=0.0321) with longer progressionfree survival (Table 5 ). In cases with tumor and stromal TIMP2 coexpression, increased overall (p=0.001) and progressionfree survival (p=0.0034) were observed (Table 5 ).
Discussion
Matrix metalloproteinases and their inhibitors (TIMPs) play a crucial regulatory role in the homeostasis of the extracellular matrix. TIMP2 has additional functions, unrelated to its antiMMP activity, that are associated with cell proliferation and survival (Bourboulia et al. 2011) . In addition to the key role of TIMP2 in the process of inhibit ing the activity of metalloproteinases, especially of MMP 2, it is also involved in activation of this enzyme along with membrane type 1 metalloproteinase (MT1MMP). The main mechanism of this process is based on the fact that MT1MMP is a specific receptor for TIMP2. The MT1 MMP/TIMP2 complex has been shown to function as a cytobiochemical active base for proMMP2, which is finally activated by another MT1MMP (Butler et al. 1998; Kinoshita et al. 1998) . In this study, we detected by immunohistochemistry the expression of TIMP2 in malignant epithelial ovarian tumors (sections originating from primary laparotomies). In addi tion, we conducted an immunocytochemical analysis of TIMP2 reactivity in six ovarian carcinoma cell lines and determined their resistance to cisplatin, paclitaxel, and topotecan. No significant correlations were found between resistance to these anticancer agents and expression of TIMP2 in the analyzed cell lines. Contrastingly, in vivo, in cases with complete response to cisplatin and paclitaxel based chemotherapy, the TIMP2 expression in the stromal compartment was higher than in patients with progressive disease, suggesting the stromal influences on tumor behav ior in a physiological environment. TIMPs, being the secreted factors, most likely have paracrine effects on the surrounding stroma, thereby affecting tumor growth, angio genesis, and sensitivity to anticancer factors. Studying TIMP1 in MDAMB231 cells and in SCID mice, Bigelow et al. (2009) observed that TIMP1 stimulates changes in gene expression in vivo distinct from those observed in vitro: TIMP1's effect on gene expression levels was more pronounced and affected more genes in vivo as compared with the in vitro analysis (approximately 600 genes vs. approximately 200 genes, respectively). Thus, studying the in vitro effects of TIMPs will not accurately reflect their true function when those proteins are overexpressed in a physi ological environment (Bigelow et al. 2009 ).
Our study revealed that expression of TIMP2 in the tumor and stromal compartments in postoperative specimens was not associated with clinicopathological parameters, such as histological tumors type, grade, and CA125 serum level at primary laparotomy. Interestingly, we demonstrated a bor derline significant association of enhanced stromal expres sion of TIMP2 and a better clinical response to chemotherapy. The KaplanMeier analysis confirmed these results, as stro mal immunoreactivity of TIMP2 had a significant impact on overall survival and progressionfree survival time (overex pression strongly correlated with a better outcome). Intriguingly, the analysis revealed a tendency toward there being a positive correlation between Ki67 overexpression and increased TIMP2 expression in ovarian cancer cells (tumor compartment).
To the best of our knowledge, this is the first study that describes TIMP2 overexpression in the stromal compartment of ovarian cancer as a favorable prognostic and predictive fac tor. It supports the assumption that TIMP2 has a pluripoten tial impact on the behavior of cancer cells. Studies of the TIMP2 expression pattern and its significance in the progno sis of clinical outcome have been discrepant and seem to depend on the type of tissue material and detection methods used (Kikkawa et al. 1997; Sakata et al. 2000; Furuya et al. 2000; Yoshida et al. 2001; Okamoto et al. 2003) . Davidson et al. (2002) demonstrated that overexpression of TIMP2 in the stroma and in cancer cells, as detected by colorimetric nonradioactive in situ mRNA hybridization, is strongly correlated with a poor outcome. Their findings point to the central role of TIMP2 in determining the outcome in ovarian cancer patients, but the main function of TIMP2 is probably related to activation of MMP2, together with MT1 MMP, rather than in inhibiting the activation of MMP2. Interestingly, Kim et al. (2006) examined the immunohisto chemical expression of TIMP2 in 52 serous ovarian tumors (12 benign, 20 borderline, and 20 malignant) and observed intracytoplasmic and membranous staining for TIMP2. Furthermore, their analysis revealed stromal TIMP2 expres sion in some cases, especially in the serous type of ovarian cancer, but this study did not correlate immunohistochemical parameters with the patient's survival. Using immunohisto chemistry, Sakata et al. (2000) suggested that overexpression of TIMP2 and the downregulation of TIMP1 might pro mote the development of ovarian carcinogenesis.
By contrast, Furuya et al. (2000) examined the neoplastic cysts of ovarian mucinous tumors for the presence of MMPs and TIMPs and reported that TIMP2 concentration in cystic fluids is less prevalent in cancer/borderline fluids than in adenoma fluids. In addition, Okamoto et al. (2003) showed that TIMP2 levels were markedly decreased in malignant tumors, as compared with normal ovarian cells. In this exper iment, ovarian clear cell carcinomas were the exception because, in these cases, TIMP2 reactivity was significantly elevated. Furthermore, Okamoto et al. (2003) also demon strated that in the ovarian clear cell carcinoma, the expression of TIMP2 was predominantly located in the cancer cells within the ovary. On the other hand, in the serous and muci nous type of ovarian cancer, the topography of TIMP2 was seen mainly in the stromal compartment of the tumor. Our study did not reveal any significant correlations between TIMP2 expression (in the stromal or tumor compartment) and histological type of tumor. These contradicting results regarding the role of TIMP2 expression in the stromal and tumor compartments of OC may reflect the analysis of both early and advancedstage tumors and, in addition, reflect the use of different methods to detect the studied protein.
In conclusion, the evaluation of TIMP2 expression in the stromal compartment of OC may be a useful prognos tic marker that can also predict the response to cisplatin and paclitaxelbased chemotherapy. Overall, the significance of TIMP2 immunoreactivity and the impact of FIGO, International Federation of Gynecology and Obstetrics; TIMP-2, tissue inhibitor of metalloproteinase 2; TIPM-2c, TIMP-2 expression in tumor compartment (cancer cells); TIMP-2s, TIMP-2 expression in the stromal compartment; TIMP2c-s, TIMP-2 coexpression in tumor and stromal compartments.
its tissue topography on patients' survival are still contro versial. Further studies are needed to fully determine the clinicopathological implications of TIMP2 expression in stromal and tumor compartments and its role in ovarian carcinogenesis.
